SCHEMBL30294672

SCHEMBL30294672

Cc1cc(F)ccc1Nc1ccccc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 5/20 0.59
AKR1C2 P52895 4/20 0.59
MEN1 O00255 3/20 0.59
AKR1B10 O60218 3/20 0.59
PTGS2 P35354 3/20 0.59
KMT2A Q03164 3/20 0.59
AKR1C1 Q04828 3/20 0.59
LMNA P02545 2/20 0.59
CYP1A2 P05177 2/20 0.59
CYP3A4 P08684 2/20 0.59
CYP2C9 P11712 2/20 0.59
AKR1B1 P15121 2/20 0.59
HIF1A Q16665 2/20 0.59
ABCB11 O95342 2/20 0.59
CHRM1 P11229 2/20 0.59
PTGS1 P23219 2/20 0.59
TRPA1 O75762 1/20 0.59
DHFR P00374 1/20 0.59
MPO P05164 1/20 0.59
NAPRT Q6XQN6 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22853331 1.00 AKR1C3 (0.59) AKR1C3AKR1C2MEN1AKR1B10PTGS2
SCHEMBL22853383 0.89 P2RY4 (0.56) AKR1C3AKR1C2MEN1AKR1B10PTGS2
SCHEMBL30294653 0.89 P2RY4 (0.56) AKR1C3AKR1C2MEN1AKR1B10PTGS2
SCHEMBL22720122 0.87 FABP4 (0.66) AKR1C3AKR1C2MEN1AKR1B10PTGS2
SCHEMBL6141067 0.86 FABP4 (0.62) AKR1C3AKR1C2MEN1AKR1B10PTGS2
SCHEMBL22853413 0.85 MAPT (0.55) PTGS2KMT2ALMNACYP1A2TDP1
SCHEMBL30294693 0.85 MAPT (0.55) PTGS2KMT2ALMNACYP1A2TDP1
SCHEMBL30294529 0.85 DHODH (0.56) AKR1C3AKR1C2MEN1KMT2AFABP4
SCHEMBL22852994 0.85 DHODH (0.56) AKR1C3AKR1C2MEN1KMT2AFABP4
SCHEMBL16489007 0.84 MAPT (0.62) AKR1C3AKR1C2MEN1AKR1B10PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B AKR1C3 2437/4885AKR1C2 2468/4885MEN1 1826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.